On May 15, 2015, we acquired Abeona Therapeutics LLC which had an exclusive license through Nationwide Children’s Hospital to the AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. The license is amortized over the life of the license of 20 years.

 

On August 3, 2016,

We also entered into a license with Stanford

for the AAV-based gene therapy EB-201 (AAV DJ COL7A1) technology, and we

perform preclinical development and perform clinical trials of a gene therapy treatment for EB based upon such in-licensed technology. EB-201 (AAV DJ COL7A1) is a pre-clinical candidate targeting a novel, AAV-mediated gene editing and delivery approach (known as homologous recombination) to correct gene mutations in skin cells (keratinocytes) for patients with

. The licenses are amortized over the life of the license of 20 years.

 

Licensed technology consists of the following

 

 

Amortization expense related to intangible assets totaled $87,000 and $174,000 for the three and six months ended June 30, 2018, respectively, and totaled $158,000 and $361,000 for the three and six months ended June 30, 2017, respectively. The aggregate estimated amortization expense for intangible assets remaining as of June 30, 2018 is as follows (in thousands):